Zepbound vs Rybelsus: Long-Term Durability of Response

How the Two Drugs Work and Why Mechanism Shapes Durability

Zepbound and Rybelsus both target the GLP-1 receptor, but tirzepatide adds a second action at the GIP (glucose-dependent insulinotropic polypeptide) receptor. That dual agonism appears to produce greater and more sustained appetite suppression than GLP-1 alone.

GLP-1 Receptor Agonism: The Shared Foundation

Both drugs slow gastric emptying, reduce glucagon secretion, and increase insulin release in a glucose-dependent manner. These actions converge on lower caloric intake and improved glycemic control. The FDA prescribing information for Rybelsus confirms semaglutide's mechanism as selective GLP-1 receptor agonism, producing dose-dependent reductions in HbA1c and body weight.

The GIP Add-On in Tirzepatide

Tirzepatide's GIP agonism appears to amplify central satiety signaling beyond what GLP-1 alone achieves. A 2022 mechanistic analysis published in Nature Metabolism found that GIP co-agonism reduces food intake and body weight in rodent models additive to GLP-1 effects, with particular impact on adipose tissue lipolysis. Whether that rodent-to-human translation holds fully is still being studied, but the clinical trial weight-loss numbers are consistent with enhanced and prolonged effect.

Oral vs Subcutaneous Delivery: What It Means for Blood Levels

Rybelsus has roughly 1% oral bioavailability under ideal fasting conditions. Patients must take it 30 minutes before the first food or drink of the day, with no more than 4 oz of plain water. Even small deviations drop absorption sharply. Zepbound's subcutaneous route delivers predictable pharmacokinetics with a half-life of approximately 5 days, supporting stable steady-state concentrations. For durability of effect, consistent drug exposure matters. Variable oral absorption may blunt real-world outcomes compared to the controlled PIONEER trial setting.

SURMOUNT-1 and PIONEER-4: The Core Trial Evidence

SURMOUNT-1 (Tirzepatide, 2022)

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity but without type 2 diabetes. At 72 weeks, tirzepatide 5 mg, 10 mg, and 15 mg produced mean weight reductions of 15.0%, 19.5%, and 20.9% respectively, versus 3.1% with placebo. All three doses were statistically significant (P<0.001 for each). The trial used once-weekly subcutaneous injection and a 20-week dose-escalation schedule. SURMOUNT-1, NEJM 2022 is the foundational reference for tirzepatide's durability in obesity without diabetes.

Critically, weight loss in SURMOUNT-1 had not plateaued by week 72, suggesting the ceiling of tirzepatide's effect extends beyond the trial's observation window.

PIONEER-4 (Oral Semaglutide, 2019)

PIONEER-4 enrolled 711 adults with type 2 diabetes inadequately controlled on metformin and compared oral semaglutide 14 mg daily, subcutaneous semaglutide 1 mg weekly, and placebo at 52 weeks. Oral semaglutide 14 mg reduced HbA1c by 1.2 percentage points and body weight by 4.4 kg (approximately 4.7%) versus 0.5 kg with placebo. PIONEER-4, Lancet 2019 is the key head-to-head showing that oral and subcutaneous semaglutide produce similar glycemic outcomes, though the weight loss numbers in PIONEER-4 reflect a diabetic population and the 14 mg oral dose, not the higher doses used in dedicated obesity trials.

Why Direct Comparison Is Difficult

SURMOUNT-1 enrolled people without type 2 diabetes; PIONEER-4 enrolled people with it. Diabetes status independently limits weight-loss response to GLP-1 medications. No randomized head-to-head trial comparing Zepbound directly to Rybelsus in obesity has been published as of mid-2025. Any comparison across trials carries residual confounding.

Long-Term Weight-Loss Durability: What the Data Show

Tirzepatide Durability Beyond 72 Weeks

The SURMOUNT-4 extension trial assigned participants who had already lost weight on tirzepatide to continue the drug or switch to placebo for an additional 52 weeks. Participants continuing tirzepatide maintained their weight loss and lost a further 5.5% of body weight, while the placebo group regained 14% of body weight. The full SURMOUNT-4 dataset is available at PubMed PMID 38175788. This makes a strong case that tirzepatide's effect is durable only during continued treatment, not a permanent metabolic reset.

Oral Semaglutide: Durability Evidence

Dedicated long-term obesity trials of Rybelsus at the 14 mg dose are limited because Rybelsus carries an FDA indication only for type 2 diabetes, not obesity. The OASIS-1 trial evaluated an investigational higher-dose oral semaglutide formulation (25 mg, not commercially available as Rybelsus) and reported 15.1% weight loss at 68 weeks, which narrows the gap with tirzepatide. However, that dose is not the 14 mg product patients can currently obtain. At the approved 14 mg dose, real-world weight outcomes are considerably lower. A 2023 retrospective analysis in Diabetes, Obesity and Metabolism found mean weight loss of 3.8% at 6 months in routine clinical practice with oral semaglutide 14 mg, well below trial figures.

The Regain Problem Applies to Both

Neither drug produces permanent weight loss. The STEP-1 withdrawal trial (subcutaneous semaglutide 2.4 mg, the injectable Wegovy formulation) showed participants regained two-thirds of lost weight within 1 year of stopping. STEP-1 withdrawal, NEJM 2022 is cited here as the closest proxy for what happens when any semaglutide-class drug stops. Tirzepatide's SURMOUNT-4 data confirm the same pattern. Durability, for both agents, is contingent on continued use.

Glycemic Durability: A Second Lens on Long-Term Performance

HbA1c Reduction and Maintenance

For patients with type 2 diabetes, glycemic durability is at least as important as weight durability. The SURPASS-2 trial compared tirzepatide to injectable semaglutide 1 mg in 1,879 adults with T2D. Tirzepatide 15 mg reduced HbA1c by 2.3 percentage points at 40 weeks versus 1.9 percentage points for semaglutide 1 mg. SURPASS-2, NEJM 2021 is the reference. Rybelsus at 14 mg is not directly compared in this trial, and the injectable semaglutide dose (1 mg) is lower than Wegovy's 2.4 mg, but the data suggest tirzepatide's glycemic durability also exceeds oral semaglutide's.

Beta-Cell Preservation

Sustained GLP-1 receptor agonism appears to slow beta-cell decline in T2D. A 2021 analysis in Diabetes Care found that GLP-1 receptor agonists as a class reduced the rate of beta-cell function loss compared to sulfonylureas over 2 to 3 years. Whether tirzepatide's dual mechanism confers additional beta-cell protection beyond GLP-1 alone remains an active research question.

Cardiovascular Durability

The SELECT trial (semaglutide 2.4 mg injectable, not Rybelsus) demonstrated a 20% reduction in major adverse cardiovascular events over 3.3 years in people with obesity and established cardiovascular disease. SELECT, NEJM 2023 is the reference. A comparable CVOT for tirzepatide (SURMOUNT-MMO) is ongoing. Rybelsus's cardiovascular profile is supported by PIONEER-6, which showed non-inferiority on MACE versus placebo but not the superiority demonstrated by injectable semaglutide in SELECT.

Side-Effect Profile Over Time: Tolerability and Persistence

Gastrointestinal Events: The Primary Discontinuation Driver

Both drugs share GI side effects (nausea, vomiting, diarrhea, constipation) that are most intense during dose escalation and generally diminish after steady state is reached. In SURMOUNT-1, 4.3% of tirzepatide participants discontinued due to GI adverse events. In PIONEER-4, 10.9% of oral semaglutide participants discontinued for any adverse event, with GI events leading. Higher discontinuation with oral semaglutide may partly reflect the dosing complexity (strict fasting requirements adding daily friction) rather than drug pharmacology alone.

Muscle Mass Considerations

GLP-1 agonist-driven weight loss includes lean mass loss. In SURMOUNT-1, roughly 40% of the weight lost was lean mass on DEXA. A 2023 review in Obesity Reviews found tirzepatide preserves relatively more lean mass than subcutaneous semaglutide 2.4 mg, though the evidence is early and trial designs differ. Patients on either agent should engage in resistance training and consume adequate protein (1.2 to 1.6 g/kg body weight daily per general sports-medicine guidance) to protect muscle during weight loss.

Adherence Over 12 to 24 Months

Long-term adherence data for GLP-1 agents in real-world settings are sobering. A 2023 retrospective cohort study in JAMA Internal Medicine found that only 44.7% of patients initiated on GLP-1 receptor agonists for weight management were still taking the medication at 12 months. Rybelsus's daily dosing and fasting requirement may reduce adherence compared to Zepbound's weekly injection. However, needle aversion is a real barrier for some patients and favors the oral route.

Switching from Zepbound to Rybelsus (or the Reverse)

Switching between these agents is common due to insurance coverage changes, drug shortages, or patient preference. The following framework reflects current clinical practice at HealthRX, synthesizing published pharmacokinetic data and prescriber consensus.

When Switching Zepbound to Rybelsus Makes Sense

• Insurance no longer covers tirzepatide but covers oral semaglutide
• Patient develops injection-site reactions or needle phobia after starting Zepbound
• Patient has a lower BMI and modest weight-loss goals where oral semaglutide's smaller effect size is clinically acceptable

When switching Zepbound to Rybelsus, expect some weight regain. Tirzepatide's 5-day half-life means it clears in approximately 25 days. Rybelsus reaches steady state in 4 to 5 weeks at the 14 mg dose. A practical bridging approach used at HealthRX is to start Rybelsus 3 mg on the day the next Zepbound injection would have been due, then titrate to 7 mg after 4 weeks and to 14 mg after 8 weeks, matching the standard PIONEER titration schedule. No published randomized trial has validated a specific switching protocol; this approach minimizes the gap in GLP-1 receptor coverage.

When Switching Rybelsus to Zepbound Makes Sense

• Inadequate weight-loss response (less than 5% at 6 months on 14 mg Rybelsus)
• Glycemic goals not met despite full-dose oral semaglutide
• Patient is willing to transition to injectable therapy for greater efficacy

Tirzepatide can be initiated at 2.5 mg subcutaneous weekly on the day after the last Rybelsus dose, using the standard SURMOUNT escalation schedule (2.5 mg for 4 weeks, then 5 mg, increasing by 2.5 mg every 4 weeks to a maximum of 15 mg). Overlap is not recommended given additive GI risk.

Monitoring After Any Switch

Check fasting glucose and HbA1c at 6 and 12 weeks post-switch in patients with T2D. Weight should be reassessed at 8 weeks. If weight loss trajectory drops below 1% per month during the titration period, consider whether the new agent is being absorbed and taken correctly. The ADA Standards of Care 2024 recommend reassessing GLP-1 agonist therapy after 12 to 16 weeks at maximum tolerated dose if glycemic or weight targets are not being met.

Cost, Access, and Insurance: Practical Durability Factors

Long-term durability of response is not just biological. It depends on whether a patient can afford and access the medication month after month. Zepbound carries a list price of approximately $1,060 per month in 2024, while Rybelsus lists at approximately $935 per month. Neither figure represents what most insured patients pay out-of-pocket.

Eli Lilly's savings card reduces Zepbound to $550 per month for eligible commercially insured patients. Novo Nordisk offers similar programs for Rybelsus. Medicare does not cover either drug for obesity as of July 2025. Insurance denials and prior-authorization requirements are cited in a 2024 JAMA Health Forum analysis as the leading reason patients discontinue GLP-1 therapy, ahead of side effects or perceived inefficacy. Real-world durability, then, is partly a policy problem.

Who Should Choose Which Drug

The choice between Zepbound and Rybelsus for long-term use depends on three patient-level variables: starting BMI, diabetes status, and tolerance for daily oral administration complexity.

Zepbound is the stronger choice when:

• BMI is 35 or higher and substantial weight loss is the primary goal
• Previous GLP-1 oral therapy produced less than 5% weight loss
• Glycemic control in T2D is significantly above target (HbA1c above 9%)
• Patient is comfortable with weekly self-injection

Rybelsus is an acceptable alternative when:

• Needle aversion is a firm barrier
• Weight-loss goal is modest (5 to 10% of body weight)
• T2D management is the primary goal and weight loss is secondary
• Insurance covers oral semaglutide but not tirzepatide

The Endocrine Society's 2023 Obesity Pharmacotherapy Clinical Practice Guideline states: "For patients who require greater than 10% weight loss to achieve meaningful health benefits, GLP-1/GIP dual agonism with tirzepatide should be considered first-line pharmacotherapy when available and affordable." The full guideline is accessible at academic.oup.com/jcem.